Stay updated on Lebrikizumab Long-term Safety Efficacy AD Clinical Trial
Sign up to get notified when there's something new on the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page.

Latest updates to the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.6.3 has replaced the previous Revision: v3.6.2 on the page, indicating a platform update.SummaryDifference0.0%

- Check18 days agoChange DetectedA new publication entry is added to Publications detailing a three-year Lebrikizumab extension study with author names; the page revision is updated to v3.6.2, replacing the prior v3.6.0.SummaryDifference0.0%

- Check32 days agoChange DetectedRecruitment status is updated to 'No longer looking for participants', signaling that the study is closed to new participants, and several help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study). Publications references were updated by adding a 2026 Lebrikizumab study citation and removing the older 2025 citation, and the Intervention/Treatment heading formatting was adjusted.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page’s Revision tag changed from v3.5.4 to v3.5.5, indicating a new build of the page. This appears to reflect a behind-the-scenes update rather than a substantive change to the study information.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page's revision tag was updated from v3.5.3 to v3.5.4, indicating a new version of the page/documentation has been published. This appears to be a minor, behind-the-scenes update rather than a substantive change to the study details or user-facing content.SummaryDifference0.0%

- Check68 days agoChange DetectedTaiwan site listing now specifies Taoyuan City rather than Taoyuan, clarifying the exact location.SummaryDifference0.0%

Stay in the know with updates to Lebrikizumab Long-term Safety Efficacy AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page.